PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11683476-5 2001 The relative receptor binding affinities of currently available AT1-receptor blockers is candesartan > irbesartan > valsartan/EXP-3174/telmisartan > tasosartan > losartan > eprosartan. Valsartan 122-131 angiotensin II receptor type 1 Homo sapiens 64-67 11963637-5 2002 AT1 receptor blockers (losartan, candesartan, irbesartan, valsartan) are available drugs in the angiotensin-II-antagonist class. Valsartan 58-67 angiotensin II receptor type 1 Homo sapiens 0-3 11561228-0 2001 Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. Valsartan 59-68 angiotensin II receptor type 1 Homo sapiens 0-30 11467764-3 2001 Valsartan is an orally active, selective antagonist of the angiotensin II-1 (AT1) receptor developed for the treatment of hypertension. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 77-80 9342580-1 1997 OBJECTIVE: Valsartan (V), a specific inhibitor of the angiotensin II receptor subtype, AT1, has been developed for treatment of hypertension. Valsartan 11-20 angiotensin II receptor type 1 Homo sapiens 54-90 11103753-3 2000 METHODS: In a placebo-controlled study in nine healthy volunteers, angiotensin II was administered intravenously for 6 hours with and without pretreatment with valsartan, a specific angiotensin II type 1 receptor antagonist. Valsartan 160-169 angiotensin II receptor type 1 Homo sapiens 182-212 11206708-1 2000 The interaction between the AT1 receptor-selective antagonist valsartan, and its human receptor, was investigated by direct radioligand binding as well as by its inhibition of angiotensin II induced inositol phosphate accumulation in CHO cells expressing human recombinant AT1 receptors. Valsartan 62-71 angiotensin II receptor type 1 Homo sapiens 28-31 11206708-1 2000 The interaction between the AT1 receptor-selective antagonist valsartan, and its human receptor, was investigated by direct radioligand binding as well as by its inhibition of angiotensin II induced inositol phosphate accumulation in CHO cells expressing human recombinant AT1 receptors. Valsartan 62-71 angiotensin II receptor type 1 Homo sapiens 273-276 11131281-5 2000 Ang II-induced migration was blocked by the Ang II type 1 (AT1) receptor antagonist valsartan in a concentration-dependent manner. Valsartan 84-93 angiotensin II receptor type 1 Homo sapiens 59-62 11206708-3 2000 It was inhibited by other AT1 receptor antagonists with the same potency order as previously described for the binding of [3H]-angiotensin II and [3H]-candesartan to human AT1 receptors (i.e. candesartan > or = EXP3174 > valsartan = irbesartan = angiotensin II > losartan). Valsartan 227-236 angiotensin II receptor type 1 Homo sapiens 26-29 11206708-3 2000 It was inhibited by other AT1 receptor antagonists with the same potency order as previously described for the binding of [3H]-angiotensin II and [3H]-candesartan to human AT1 receptors (i.e. candesartan > or = EXP3174 > valsartan = irbesartan = angiotensin II > losartan). Valsartan 227-236 angiotensin II receptor type 1 Homo sapiens 172-175 11206708-4 2000 When valsartan and angiotensin II were applied simultaneously to the CHO-AT1 cells. Valsartan 5-14 angiotensin II receptor type 1 Homo sapiens 73-76 11206708-6 2000 Hence, valsartan interacts with the AT1 receptor in a manner that is competitive with angiotensin II. Valsartan 7-16 angiotensin II receptor type 1 Homo sapiens 36-39 11206708-10 2000 In agreement, pre-incubation of the CHO-AT1 cells with 5 and 50 nM valsartan produced a partial inhibition of the angiotensin II induced increase of the free intracellular calcium concentration. Valsartan 67-76 angiotensin II receptor type 1 Homo sapiens 40-43 11206708-13 2000 These kinetic data suggest that the insurmountable inhibition by valsartan is related to its relatively slow dissociation from the human AT1 receptors. Valsartan 65-74 angiotensin II receptor type 1 Homo sapiens 137-140 12555316-1 2000 Valsartan, an angiotensin II antagonist with a potent and highly selective effect on AT1 receptors, has been found effective and safe in several randomized, controlled studies versus a placebo, other antihypertensive agents, or other angiotensin II antagonists. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 85-88 9761285-8 1998 The AT1 antagonist CGP48933 (10(-8) to 10(-12) M), but not the AT2 antagonist CGP42112 (10(-8) to 10(-12) M), inhibited AII (10(-8) M)-induced proliferation and migration in a concentration-dependent manner (P < 0.05). Valsartan 19-27 angiotensin II receptor type 1 Homo sapiens 4-7 9342579-13 1997 Indirect evidence of AT1 blockade by valsartan is demonstrated by an increase of plasma Ang II and by a blunted DBP response to passive tilting. Valsartan 37-46 angiotensin II receptor type 1 Homo sapiens 21-24 35345577-0 2022 Association of AGTR1 A1166C and CYP2C9*3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan. Valsartan 96-105 angiotensin II receptor type 1 Homo sapiens 15-20 7980530-8 1994 The effects of AI were reduced by the ACE inhibitor benazeprilat, while those of AII were prevented by valsartan, an AT1 antagonist. Valsartan 103-112 angiotensin II receptor type 1 Homo sapiens 117-120 7867676-1 1994 Valsartan (CGP 48933), a specific blocker of the angiotensin II (Ang II) receptor subtype 1 (AT1 receptor) was administered in single, oral doses of 40 mg and 80 mg to six healthy, normotensive male volunteers in a double-blind, placebo-controlled, randomized crossover trial. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 93-96 25346502-12 2014 The expression of AGTR1 was up-regulated after alcohol exposure, and was blocked by valsartan pretreatment. Valsartan 84-93 angiotensin II receptor type 1 Homo sapiens 18-23 35345577-8 2022 After adjustment for demographic and environmental factors, the CC + AC genotype of AGTR1 A1166C was markedly linked to better hypertension control with valsartan treatment compared to the AA genotype (odds ratio: 2.836, 95% confidence interval: 1.199-6.705, P = 0.018). Valsartan 153-162 angiotensin II receptor type 1 Homo sapiens 84-89 35345577-10 2022 Conclusions: The current data suggested that the AGTR1 A1166 C polymorphism may be associated with the antihypertensive effect of valsartan, and carriers with AC and CC genotypes may have a better antihypertensive efficacy response to valsartan treatment. Valsartan 130-139 angiotensin II receptor type 1 Homo sapiens 49-54 35345577-10 2022 Conclusions: The current data suggested that the AGTR1 A1166 C polymorphism may be associated with the antihypertensive effect of valsartan, and carriers with AC and CC genotypes may have a better antihypertensive efficacy response to valsartan treatment. Valsartan 235-244 angiotensin II receptor type 1 Homo sapiens 49-54 35345577-2 2022 The present study aimed to investigate whether the antihypertensive effect of the ARB drug valsartan was associated with angiotensin II type 1 receptor (AGTR1) gene polymorphism (A1166 C) and cytochrome P450 enzyme 2C9 (CYP2C9) gene polymorphism (CYP2C9*3). Valsartan 91-100 angiotensin II receptor type 1 Homo sapiens 121-151 35345577-2 2022 The present study aimed to investigate whether the antihypertensive effect of the ARB drug valsartan was associated with angiotensin II type 1 receptor (AGTR1) gene polymorphism (A1166 C) and cytochrome P450 enzyme 2C9 (CYP2C9) gene polymorphism (CYP2C9*3). Valsartan 91-100 angiotensin II receptor type 1 Homo sapiens 153-158 33203141-13 2020 Thus, NEP/angiotensin receptor type 1 (AT1R) inhibitor sacubitril/valsartan (SAC/VAL) may increase levels of these molecules and block AT1Rs required for ACE2 endocytosis in SARS-CoV-2 infection. Valsartan 66-75 angiotensin II receptor type 1 Homo sapiens 39-43 33955183-0 2021 The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Valsartan 43-52 angiotensin II receptor type 1 Homo sapiens 4-34 33955183-3 2021 Here, we investigated if the angiotensin II type 1 receptor (AT1R) blocker valsartan alters the expression of renin-angiotensin system (RAS) components, including ACE2, in human adipose tissue (AT) and skeletal muscle. Valsartan 75-84 angiotensin II receptor type 1 Homo sapiens 29-59 33955183-3 2021 Here, we investigated if the angiotensin II type 1 receptor (AT1R) blocker valsartan alters the expression of renin-angiotensin system (RAS) components, including ACE2, in human adipose tissue (AT) and skeletal muscle. Valsartan 75-84 angiotensin II receptor type 1 Homo sapiens 61-65 32087363-2 2020 Angiotensin II type 1 (AT1) receptor antagonists, e.g., candesartan, telmisartan, irbesartan, losartan and valsartan, show high affinities and long-lasting bindings to the receptor, making them preferred medications for hypertension treatment. Valsartan 107-116 angiotensin II receptor type 1 Homo sapiens 0-36 31803758-3 2019 With this in mind, we investigated whether TGR(hAGT)L1623 transgenic rats express the human sequence of Ang-(1-12) before and following a 2-week oral therapy with the type I Ang II receptor (AT1-R) antagonist valsartan. Valsartan 209-218 angiotensin II receptor type 1 Homo sapiens 191-196 31307032-3 2019 Although angiotensin II receptor type 1 -(AT1-R) antagonists such as valsartan and telmisartan have a significant cardiovascular protective effect, the molecular basis of this class of drugs in VSMC proliferation and migration remains elusive. Valsartan 69-78 angiotensin II receptor type 1 Homo sapiens 42-47 30998981-6 2019 Ang II significantly increased the macroscopic BKCa currents at the whole cell level, while increased the open probability and decreased the mean close time of BKCa channels at the single channel level with AT1R blockade by valsartan in NP. Valsartan 224-233 angiotensin II receptor type 1 Homo sapiens 207-211 30212210-0 2018 Trans and Cis Conformations of the Antihypertensive Drug Valsartan Respectively Lock the Inactive and Active-like States of Angiotensin II Type 1 Receptor: A Molecular Dynamics Study. Valsartan 57-66 angiotensin II receptor type 1 Homo sapiens 124-154 27719743-1 2016 OBJECTIVE: Sacubitril/valsartan (LCZ696) provides a novel therapeutic approach of neurohormonal modulation in heart failure via simultaneous inhibition of neprilysin and blockade of the angiotensin II type-1 receptor. Valsartan 22-31 angiotensin II receptor type 1 Homo sapiens 186-216 28338173-0 2017 Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 18-21 28338173-4 2017 In this study, we attempted to explore the effect of valsartan on AT1-AA-induced apoptosis in endothelial progenitor cells. Valsartan 53-62 angiotensin II receptor type 1 Homo sapiens 66-69 28338173-10 2017 RESULTS: MTT assays showed valsartan significantly inhibited AT1-AA- induced decline of the viability of EPCs. Valsartan 27-36 angiotensin II receptor type 1 Homo sapiens 61-64 28338173-11 2017 DAPI staining and flow cytometry results indicated valsartan inhibited AT1-AA-induced decline of the viability of EPCs via inhibiting AT1-AA-induced apoptosis. Valsartan 51-60 angiotensin II receptor type 1 Homo sapiens 71-74 28338173-11 2017 DAPI staining and flow cytometry results indicated valsartan inhibited AT1-AA-induced decline of the viability of EPCs via inhibiting AT1-AA-induced apoptosis. Valsartan 51-60 angiotensin II receptor type 1 Homo sapiens 134-137 28338173-12 2017 Furthermore, the increasing of reactive oxygen species, intracellular calcium and calpain activity induced by AT1-AA in EPCs were also recovered after pre-treated with valsartan. Valsartan 168-177 angiotensin II receptor type 1 Homo sapiens 110-113 28338173-13 2017 Meanwhile, the upregulation of p-ERK, p-eIF-2a and CHOP, downregulation of Bcl-2, and activation of Caspase-3 caused by AT1-AA were reversed after pre-incubated with valsartan. Valsartan 166-175 angiotensin II receptor type 1 Homo sapiens 120-123 28338173-14 2017 CONCLUSIONS: Valsartan could inhibit AT1-AA-induced apoptosis through inhibiting oxidative stress mediated ER stress in EPCs. Valsartan 13-22 angiotensin II receptor type 1 Homo sapiens 37-40 27542885-2 2017 We hypothesized that sacubitril/valsartan (LCZ696), which augments NP through neprilysin inhibition while blocking angiotensin II type-1 (AT1 )-receptors, improves insulin sensitivity, lipid mobilization, and oxidation. Valsartan 32-41 angiotensin II receptor type 1 Homo sapiens 115-141 27542885-6 2017 Results confirm that sacubitril/valsartan treatment leads to a metabolic benefit in the study population and supports the relevance of neprilysin inhibition along with AT1 -receptor blockade in the regulation of human glucose and lipid metabolism. Valsartan 32-41 angiotensin II receptor type 1 Homo sapiens 168-171 29500454-2 2018 We have recently demonstrated that sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, which blocks the angiotensin II type-1 receptor and augments natriuretic peptide levels, improved peripheral insulin sensitivity in obese hypertensive patients. Valsartan 46-55 angiotensin II receptor type 1 Homo sapiens 143-173 28178430-1 2017 Valsartan (VAL), an antagonist of angiotensin II receptor type 1, has antihypertensive and multiple cardiovascular protective effects. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 34-64 28178430-1 2017 Valsartan (VAL), an antagonist of angiotensin II receptor type 1, has antihypertensive and multiple cardiovascular protective effects. Valsartan 11-14 angiotensin II receptor type 1 Homo sapiens 34-64 26931777-2 2016 Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of neprilysin (neutral endopeptidase 24.11; NEP) and blockade of the angiotensin II type-1 (AT1) receptor. Valsartan 11-20 angiotensin II receptor type 1 Homo sapiens 188-224 28164602-1 2016 BACKGROUND: In order to investigate how valsartan-the angiotensin II 1 receptor (AT1R) antagonist-affects the expressions of AT1R antigen, matrix metalloproteinases (MMPs) -2 and -9 in carcinoma of urinary bladder (CUB) cell lines with different invasive abilities. Valsartan 40-49 angiotensin II receptor type 1 Homo sapiens 54-79 28164602-1 2016 BACKGROUND: In order to investigate how valsartan-the angiotensin II 1 receptor (AT1R) antagonist-affects the expressions of AT1R antigen, matrix metalloproteinases (MMPs) -2 and -9 in carcinoma of urinary bladder (CUB) cell lines with different invasive abilities. Valsartan 40-49 angiotensin II receptor type 1 Homo sapiens 81-85 28164602-1 2016 BACKGROUND: In order to investigate how valsartan-the angiotensin II 1 receptor (AT1R) antagonist-affects the expressions of AT1R antigen, matrix metalloproteinases (MMPs) -2 and -9 in carcinoma of urinary bladder (CUB) cell lines with different invasive abilities. Valsartan 40-49 angiotensin II receptor type 1 Homo sapiens 125-129 28164602-7 2016 CONCLUSIONS: AngII promotes the MMP2 and MMP9 expressions (both protein and gene levels) in CUB cells through AT1R, but their expressions can be effectively inhibited by valsartan, the AngII inhibitor. Valsartan 170-179 angiotensin II receptor type 1 Homo sapiens 110-114 26223916-8 2015 Blockade of AT1R with valsartan decreased TRAF6 and p-ERK1/2 protein expression after IH exposure. Valsartan 22-31 angiotensin II receptor type 1 Homo sapiens 12-16 25109475-3 2014 We tested whether valsartan independent of Ang II type 1 receptor (AT1R) can reduce tissue factor (TF) and toll-like receptor (TLR)-2 and -4 by regulating Egr-1 in THP-1 cells and aorta in streptozotocin-induced diabetic mice. Valsartan 18-27 angiotensin II receptor type 1 Homo sapiens 67-71 25591555-2 2015 This study aimed to investigate the inhibitory effects of AT 1 R antagonist valsartan on platelet aggregation and the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension. Valsartan 76-85 angiotensin II receptor type 1 Homo sapiens 58-64 25591555-11 2015 CONCLUSIONS: AT 1 R antagonist valsartan decreases platelet activity by attenuating COX-2/TXA 2 expression through p38MAPK and NF-kB pathways and reduces the occurrence of cardio-cerebral thrombotic events in elderly patients with hypertension. Valsartan 31-40 angiotensin II receptor type 1 Homo sapiens 13-19 24372930-5 2014 METHODS: Here, we report a case of lithium toxicity during concomitant treatment with valsartan, an AT1 blocker, in a patient who previously displayed a stable serum lithium level. Valsartan 86-95 angiotensin II receptor type 1 Homo sapiens 100-103 24844704-1 2014 Valsartan is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin, and is safe and well tolerated in hypertensive patients. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 37-67 24070321-7 2013 EXPERT OPINION: Azilsartan medoxomil has a potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors, which may play a role in its superior blood pressure (BP) -lowering efficacy compared with other drugs, including ramipril, candesartan, valsartan or olmesartan, without an increase of side effects. Valsartan 265-274 angiotensin II receptor type 1 Homo sapiens 113-116 25762441-4 2014 These improvements could be inhibited by specific AT1 receptor blocker valsartan, NF-kappaB blocker pyrrolidine dithiocarbamate (PDTC), and specific short peptides from the second extracellular loop of AT1 receptor. Valsartan 71-80 angiotensin II receptor type 1 Homo sapiens 50-53 24219285-9 2013 Additionally, these Ang II-mediated reductions could be attenuated by AT1R antagonist valsartan. Valsartan 86-95 angiotensin II receptor type 1 Homo sapiens 70-74 23426512-5 2013 After pretreatment with Valsartan (a specific inhibitor of AT1R, 10 mumol/L), 25, 100 and 250 nmol/L AngII stimulated BK(Ca) activity significantly in a dose response manner. Valsartan 24-33 angiotensin II receptor type 1 Homo sapiens 59-63 22803969-1 2013 Thermal behavior of angiotensin II type 1 (AT1) receptor antagonist, Valsartan (VAL), was examined employing thermogravimetric analysis (TGA), standard differential scanning calorimetry (DSC) and temperature-modulated differential scanning calorimetry (TMDSC). Valsartan 69-78 angiotensin II receptor type 1 Homo sapiens 20-56 22803969-1 2013 Thermal behavior of angiotensin II type 1 (AT1) receptor antagonist, Valsartan (VAL), was examined employing thermogravimetric analysis (TGA), standard differential scanning calorimetry (DSC) and temperature-modulated differential scanning calorimetry (TMDSC). Valsartan 80-83 angiotensin II receptor type 1 Homo sapiens 20-56 23553863-3 2013 OBJECTIVE: The purpose of this study was to investigate the effects of the angiotensin II type 1 receptor blocker valsartan (VAL) on skeletal muscle fatty acid (FA) handling in subjects with IGM. Valsartan 114-123 angiotensin II receptor type 1 Homo sapiens 75-105 23553863-3 2013 OBJECTIVE: The purpose of this study was to investigate the effects of the angiotensin II type 1 receptor blocker valsartan (VAL) on skeletal muscle fatty acid (FA) handling in subjects with IGM. Valsartan 125-128 angiotensin II receptor type 1 Homo sapiens 75-105 22884153-2 2012 Telmisartan is reported to have partial peroxisome proliferator-activated receptor (PPAR)-gamma activating properties and has been referred to as selective PPAR modulators, but valsartan just blocks angiotensin II (AngII) type 1 (AT1) receptors. Valsartan 177-186 angiotensin II receptor type 1 Homo sapiens 199-234 22045314-6 2012 Very interestingly, this effect of valsartan was also observed in THP-1 cells treated with angiotensin II type 1 (AT1) siRNA or a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist as well as macrophages from AT1a receptor-knockout mice. Valsartan 35-44 angiotensin II receptor type 1 Homo sapiens 91-112 22045314-6 2012 Very interestingly, this effect of valsartan was also observed in THP-1 cells treated with angiotensin II type 1 (AT1) siRNA or a peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist as well as macrophages from AT1a receptor-knockout mice. Valsartan 35-44 angiotensin II receptor type 1 Homo sapiens 114-117 23038657-5 2012 All compounds are designed as hybrid molecules, potentially combining the NO-donating properties of organic nitrates with the AT1-blocking activity of valsartan or the phosphodiesterase-III-inhibiting effect of cilostazol. Valsartan 151-160 angiotensin II receptor type 1 Homo sapiens 126-129 22768174-4 2012 Therefore, we examined whether 26-wks treatment with the angiotensin II type 1 receptor blocker valsartan affects AT function in humans with impaired glucose metabolism (IGM). Valsartan 96-105 angiotensin II receptor type 1 Homo sapiens 57-87 17878892-10 2008 Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Valsartan 56-65 angiotensin II receptor type 1 Homo sapiens 101-104 20463030-7 2010 Ang-II application to cardiomyocyte nuclei enhanced NFkappaB mRNA expression, a response that was suppressed by co-administration of AT1R (valsartan) and/or AT2R (PD123177) blockers. Valsartan 139-148 angiotensin II receptor type 1 Homo sapiens 133-137 20432929-8 2010 This Ang II-activated PI3-K/Akt cascade was significantly inhibited by valsartan, an AT1 receptor specific blocker (P<0.05), whereas enhanced by PD123319, an AT2 receptor antagonist (P<0.05). Valsartan 71-80 angiotensin II receptor type 1 Homo sapiens 85-88 19687742-1 2009 The objective of this study was to investigate the effects of angiotensin II and valsartan, an angiotensin II type 1 receptor (AT1R) blocker, combined with gamma-radiation, on vascular endothelial growth factor (VEGF) expression, radiosensitivity, invasive potential, and proliferation activity of nasopharyngeal carcinoma (CNE-2) in vitro. Valsartan 81-90 angiotensin II receptor type 1 Homo sapiens 127-131 19307231-0 2009 Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 39-69 19307231-1 2009 AIMS: Valsartan, a selective angiotensin II type 1 receptor (AT1R) blocker, has beneficial effects in the cardiovascular system in part by its increase of nitric oxide (NO) bioavailability, yet the mechanisms are unclear. Valsartan 6-15 angiotensin II receptor type 1 Homo sapiens 29-59 19307231-1 2009 AIMS: Valsartan, a selective angiotensin II type 1 receptor (AT1R) blocker, has beneficial effects in the cardiovascular system in part by its increase of nitric oxide (NO) bioavailability, yet the mechanisms are unclear. Valsartan 6-15 angiotensin II receptor type 1 Homo sapiens 61-65 19307231-8 2009 In addition, valsartan increased the tyrosine residue phosphorylation of AT1R, which was attenuated by inhibition of Src but not PI3K activities. Valsartan 13-22 angiotensin II receptor type 1 Homo sapiens 73-77 19307231-9 2009 Valsartan also suppressed the interaction of eNOS and AT1R, which was blocked by Src or PI3K inhibition. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 54-58 19307231-11 2009 Valsartan-induced AT1R phosphorylation depends on Src but not PI3K, whereas valsartan-induced suppression of AT1R-eNOS interaction depends on Src/PI3K/Akt signalling. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 18-22 19307231-11 2009 Valsartan-induced AT1R phosphorylation depends on Src but not PI3K, whereas valsartan-induced suppression of AT1R-eNOS interaction depends on Src/PI3K/Akt signalling. Valsartan 76-85 angiotensin II receptor type 1 Homo sapiens 109-113 21315062-0 2011 Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Valsartan 35-44 angiotensin II receptor type 1 Homo sapiens 20-23 21315062-1 2011 Valsartan is a marketed drug with high affinity to the type 1 angiotensin (AT1) receptor. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 75-78 20399995-1 2010 BACKGROUND: Valsartan is a selective angiotensin II type 1 receptor blocker indicated for the treatment of hypertension. Valsartan 12-21 angiotensin II receptor type 1 Homo sapiens 37-67 19843489-1 2009 BACKGROUND: Valsartan is a nonpeptide, orally active angiotensin II type 1 receptor blocker used to treat hypertension alone or in combination with other antihypertensive agents. Valsartan 12-21 angiotensin II receptor type 1 Homo sapiens 53-83 19256500-0 2009 Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations. Valsartan 22-31 angiotensin II receptor type 1 Homo sapiens 55-58 19256500-1 2009 The conformational properties of AT1 antagonist valsartan have been analyzed both in solution and at the binding site of the receptor. Valsartan 48-57 angiotensin II receptor type 1 Homo sapiens 33-36 19256500-9 2009 In silico docking and Molecular Dynamic studies were applied to study binding of valsartan at the AT1 receptor site models, explicitly solvated and embedded in lipid bilayers and solvent molecules. Valsartan 81-90 angiotensin II receptor type 1 Homo sapiens 98-101 19911855-1 2009 Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding of angiotensin II to the angiotensin II type 1 receptor. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 119-149 17964282-3 2007 Valsartan, a selective Ang II type 1 (AT1) receptor blocker, and N-acetylcysteine, an antioxidant, inhibited both of these modifications, indicating the contribution of AT1 receptor and reactive oxygen species to oxidation of Prx2 and phosphorylation of GRP58 by Ang II. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 38-41 17964282-3 2007 Valsartan, a selective Ang II type 1 (AT1) receptor blocker, and N-acetylcysteine, an antioxidant, inhibited both of these modifications, indicating the contribution of AT1 receptor and reactive oxygen species to oxidation of Prx2 and phosphorylation of GRP58 by Ang II. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 169-172 17393691-8 2007 In cultured fibroblasts, Ang II stimulation significantly increased DNA synthesis (P < 0.05 vs negative control), which was inhibited by valsartan, an AT1 receptor blocker, but augmented by PD123319, an AT2 receptor antagonist. Valsartan 140-149 angiotensin II receptor type 1 Homo sapiens 154-157 17875818-9 2007 Finally, ATRAP knockdown by small-interference RNA activated angiotensin II-induced c-fos gene expression, which was effectively inhibited by valsartan, an AT1R-specific antagonist. Valsartan 142-151 angiotensin II receptor type 1 Homo sapiens 156-160 17322151-0 2007 Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. Valsartan 57-66 angiotensin II receptor type 1 Homo sapiens 15-45 16713009-3 2006 We studied the effect of a selective AT1 antagonist, valsartan, on glucose, lipid metabolism and the preheparin LPL mass in 55 patients with type 2 diabetes and hypertension. Valsartan 53-62 angiotensin II receptor type 1 Homo sapiens 37-40 17086018-4 2006 Angiotensin II type 1 receptor blockade with valsartan improved vascular compliance but not flow-mediated dilation. Valsartan 45-54 angiotensin II receptor type 1 Homo sapiens 0-30 16097371-10 2005 Because we previously demonstrated that both the up-regulation of gp91phox and the acceleration of cellular senescence in Ang II-stimulated EPCs could be abolished by pre-treatment with the AT1R- specific antagonist, valsartan, we also explored the effect of estrogen on AT1R expression. Valsartan 217-226 angiotensin II receptor type 1 Homo sapiens 190-194 16195625-2 2005 Valsartan, an angiotensin II type 1 receptor blocker, may improve myocardial fibrosis in patients with HCM. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 14-44 15677497-7 2005 High glucose-induced JAK2 activation was blunted by both ACE inhibition (100 nmol/l ramipril) and AT1 antagonism (1 mumol/l valsartan), thus revealing that the effects are mediated by autocrine Ang II production. Valsartan 124-133 angiotensin II receptor type 1 Homo sapiens 98-101 15907144-12 2005 Conversely, a single, exploratory randomised trial demonstrated that the selective AT1R antagonist valsartan significantly reduced stent restenosis after PCI. Valsartan 99-108 angiotensin II receptor type 1 Homo sapiens 83-87 15005273-6 2004 Both the angiotensin type 1 (AT1) receptor antagonist (valsartan: 200 nmol/l) and the PKC inhibitor, bisindolylmaleimide (GFX: 10 micromol/l) reduced Ang II-induced KDR mRNA expression to almost the control level. Valsartan 55-64 angiotensin II receptor type 1 Homo sapiens 29-32 14643571-9 2003 Valsartan (an AT1R antagonist, at 1 to 10 nmol/L) significantly increased AT2R mRNA of HUVEC. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 14-18 14871033-0 2003 Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. Valsartan 53-62 angiotensin II receptor type 1 Homo sapiens 13-43 14620933-10 2003 The angiotensin II subtype 1 (AT1) receptor antagonist valsartan suppressed the elevated blood pressure completely and left ventricular hypertrophy incompletely, but did not affect the other phenotypes. Valsartan 55-64 angiotensin II receptor type 1 Homo sapiens 30-33 12846741-9 2003 Valsartan and PD123319 were used to block the effects of angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors of angiotensin II, respectively. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 80-83 12846741-11 2003 Angiotensin II induced TIMP-1, mRNA, and protein expressions in time- and dose-dependent manners, which could be inhibited by the AT1 receptor antagonist valsartan, but not by the AT2 antagonist PD123319. Valsartan 154-163 angiotensin II receptor type 1 Homo sapiens 130-133 12515751-0 2003 Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Valsartan 99-108 angiotensin II receptor type 1 Homo sapiens 59-89 15485399-3 2004 METHODS: Streptozotocin-induced diabetic and control animals were randomized (N=10/group) to receive the AT1 antagonist valsartan at a dose of 30 mg/kg/day by oral gavage for 24 weeks, or no intervention. Valsartan 120-129 angiotensin II receptor type 1 Homo sapiens 105-108 15071355-1 2004 Valsartan selectively blocks angiotensin II binding to the AT1 receptor. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 59-62 15071355-2 2004 ince platelet activation plays a key role in the pathogenesis of vascular disease, and because AT1 receptors are present on the platelet surface, we assessed the in vitro effects of valsartan and its metabolite, valeryl 4-hydroxy valsartan (V4HV), on platelets in 30 subjects with multiple risk factors for cardiovascular disease. Valsartan 182-191 angiotensin II receptor type 1 Homo sapiens 95-98 14973301-4 2004 The AT(1)R antagonist valsartan (160 mg) was given to all the subjects, and blood samples were taken for pharmacokinetic analysis. Valsartan 22-31 angiotensin II receptor type 1 Homo sapiens 4-10 12409989-2 2002 Valsartan, a potent specific angiotensin II type 1 receptor blocker, may produce beneficial effects in heart failure. Valsartan 0-9 angiotensin II receptor type 1 Homo sapiens 29-59